Higher baseline monocyte counts, along with preserved basophils and low C-reactive protein, independently predict complete remission on anti-IgE therapy for CSU.

MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –– Up to 30% of people with membranous nephropathy progress to ...

Women are more likely to experience chronic pain, studies have found, and their pain lasts longer, on average. New research ...

A new study reveals that the predictive power of key inflammatory markers, such as C-reactive protein, shifts fundamentally ...

Can fragments of tumor DNA in the blood predict whether chemotherapy will be effective? Researchers at the Princess Máxima ...

Researchers say collective results highlight the therapeutic potential of enhancing IL-10+ monocytes for treating sex-biased pain conditions.

BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the combination regimen of Venclexta® (venetoclax) ...

Avoid common mistakes in multiplexing protein secretion assays. Discover best practices to ensure accurate results.

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...